



Corrigendum

**Corrigendum to “Discovery of OT4003, a Novel, Potent and Orally Active Cys-LT₁ Receptor Antagonist”
(*Bioorg. Med. Chem.* 1997, 5, 415)[†]**

Ole Tværmose-Nielsen,^a Schneur Rachlin,^a Heinz Dannacher,^a Fredrik Björkling,^{a,*}
Dorte Kirstein,^b Erik Bramm,^c Christain Kærgaard Nielsen,^c Jens Thing Mortensen^d
and Lise Binderup^b

^aDepartment of Chemistry, Leo Pharmaceutical Products, Industriparken 55, DK-2750 Ballerup, Denmark

^bDepartment of Biochemistry, Leo Pharmaceutical Products, Industriparken 55, DK-2750 Ballerup, Denmark

^cDepartment of Pharmacology, Leo Pharmaceutical Products, Industriparken 55, DK-2750 Ballerup, Denmark

^dDepartment of Toxicology, Leo Pharmaceutical Products, Industriparken 55, DK-2750 Ballerup, Denmark

The determination of the absolute configuration of the published compounds is incorrect. On page 420, (*S*)-(-)-ethyl 2-bromo hexanoate is the correct configuration of the key compound used in the determination of the absolute configuration.

As a consequence, the correct absolute configuration of compound **12**, is (*R*)-(+)-E-2-[2-(3-(2-(7-chloroquinolin-2-yl)ethenyl)phenylamino-methyl)phenoxy]-hexenoic acid, and the correct configuration of compounds **24**, **29** and **30**, is (*R*)-(+)-**24**, (*R*)-(+)-**29** and (*R*)-(+)-**30** respectively.

*Corresponding author. Tel.: +45-44-92-38-00; fax: +45-44-94-55-10;
e-mail: fredrik.bjorkling@leo.dk

[†]PII of original article: S0968-0896(96)00253-2